| Literature DB >> 35208620 |
Jurgita Mikolaitytė1, Jolita Badarienė1,2, Roma Puronaitė2,3,4, Alma Čypienė1,2, Irma Rutkauskienė4, Jolanta Dadonienė5, Aleksandras Laucevičius1,2.
Abstract
Background andEntities:
Keywords: clusters of cardiovascular risk factors; hyperuricaemia; metabolic syndrome; uric acid
Mesh:
Substances:
Year: 2022 PMID: 35208620 PMCID: PMC8879816 DOI: 10.3390/medicina58020297
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Clinical characteristics of participants in quartiles of serum uric acid level.
| Women ( | Men ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 |
| Q1 | Q2 | Q3 | Q4 |
| |
|
| 95 | 96 | 97 | 98 | 53 | 57 | 55 | 55 | ||
| SUA, μmol/L | 242.35 ± 36.05 | 304.79 ± 14.85 | 354.67 ± 16.21 | 443.41 ± 55.96 | <0.001 | 312.06 ± 34.50 | 374.70 ± 12.60 | 423.98 ± 17.28 | 511.45 ± 42.73 | <0.001 |
| Age, years | 57.89 ± 3.95 | 57.13 ± 4.47 | 57.90 ± 4.27 | 57.66 ± 4.01 | 0.577 | 48.36 ± 3.67 | 47.84 ± 4.20 | 46.22 ± 4.39 | 45.62 ± 3.75 | 0.001 |
| Weight, kg | 80.62 ± 11.84 | 85.55 ± 13.63 | 89.04 ± 14.14 | 92.31 ±14.20 | <0.001 | 98.09 ±10.21 | 101.37 ± 13.32 | 103.36 ± 10.34 | 109.80 ± 12.19 | <0.001 |
| BMI, kg/m2 | 30.28 ± 4.47 | 31.51 ± 4.34 | 33.22 ± 4.94 | 34.06 ± 4.82 | <0.001 | 30.86 ± 3.00 | 31.08 ± 3.31 | 32.03 ± 3.25 | 33.60 ± 3.89 | <0.001 |
| WC, cm | 97.37 ± 9.05 | 101.04 ± 10.33 | 103.36 ± 11.73 | 104.22 ± 9.66 | <0.001 | 105.49 ± 6.30 | 106.82 ± 7.81 | 109.02 ± 7.50 | 110.94 ± 8.14 | <0.001 |
| TC, mmol/L | 6.09 ± 1.46 | 6.03 ± 1.25 | 6.15 ± 1.25 | 6.12 ± 1.41 | 0.885 | 5.92 ± 2.19 | 6.08 ± 1.38 | 5.89 ± 1.16 | 5.99 ± 1.41 | 0.409 |
| LDL-C, mmol/L | 3.83 ± 1.24 | 3.87 ± 1.07 | 3.96 ± 1.02 | 3.75 ± 1.14 | 0.4 | 3.48 ± 1.16 | 3.71 ± 1.01 | 3.60 ± 1.02 | 3.70 ± 1.25 | 0.825 |
| HDL-C, mmol/L | 1.41 ± 0.34 | 1.34 ± 0.27 | 1.32 ± 0.25 | 1.25 ± 0.29 | 0.004 | 1.01 ± 0.22 | 1.11 ± 0.25 | 1.04 ± 0.19 | 1.03 ± 0.23 | 0.211 |
| TG, mmol/L | 1.88 ± 1.21 | 1.92 ± 1.87 | 1.89 ± 0.89 | 2.42 ± 1.49 | 0.002 | 3.99 ± 9.17 | 2.63 ± 1.73 | 2.76 ± 2.10 | 2.86 ± 1.43 | 0.017 |
| Plasma glucose, mmol/L | 6.66 ± 2.00 | 6.65 ± 2.18 | 6.58 ± 1.47 | 6.76 ± 1.66 | 0.197 | 7.32 ± 2.62 | 6.37 ± 1.82 | 6.05 ± 0.55 | 6.41 ± 1.08 | 0.039 |
| MetS components | 3.66 ± 0.74 | 3.75 ± 0.75 | 3.78 ± 0.78 | 4.10 ± 0.79 | <0.001 | 3.77 ± 0.80 | 3.74 ± 0.70 | 3.89 ± 0.79 | 4.15 ± 0.70 | 0.019 |
| SBP, mmHg | 134.60 ± 13.65 | 136.47 ± 15.96 | 141.07 ± 15.90 | 138.69 ± 15.16 | 0.022 | 137.87 ± 13.05 | 134.18 ± 13.15 | 137.02 ± 14.18 | 141.44 ± 14.48 | 0.036 |
| DBP, mmHg | 79.67 ± 8.82 | 80.39 ± 9.80 | 82.02 ± 8.60 | 81.56 ± 9.24 | 0.224 | 84.81 ± 8.48 | 84.14 ± 9.38 | 84.56 ± 10.83 | 87.18 ± 9.09 | 0.259 |
SUA—serum uric acid; BMI—body mass index; WC—waist circumference; TC—total cholesterol; LDL-C—low-density lipoprotein cholesterol; HDL-C—high-density lipoprotein cholesterol; TG—triglycerides; MetS—metabolic syndrome; SBP—systolic blood pressure; DBP—diastolic blood pressure.
Figure 1Prevalence of major cardiovascular disease risk factors in different levels of serum uric acid.
Figure 2Proportions of metabolic syndrome risk number gathered in each quartile (%) for men and women.
Figure 3Metabolic syndrome components distribution according to the number of clusters (%) in men and women. BP—blood pressure; WC—waist circumference; TG—triglycerides; HDL-C—high-density lipoprotein cholesterol; PG—plasma glucose.
Prevalence of clusters of MetS components and SUA.
| Risk Factors Combination | Men ( | Women ( | ||||
|---|---|---|---|---|---|---|
|
| % | SUA, μmol/L |
| % | SUA, μmol/L | |
| 5 risks factors | ||||||
| GHTBW | 52 | 23.6 | 418.92 ± 84.49 | 90 | 23.3 | 373.12 ± 100.31 |
| 4 risks factors | ||||||
| GTBW | 42 | 19.1 | 436.76 ± 76.51 | 50 | 13.0 | 327.68 ± 77.73 |
| GHBW | 19 | 8.6 | 395.32 ± 92.73 | 52 | 13.5 | 342.90 ± 74.47 |
| HTBW | 13 | 5.9 | 413.92 ± 67.39 | 23 | 6.0 | 347.35 ± 69.92 |
| GHTB | 11 | 5.0 | 400.91 ± 75.49 | 8 | 2.1 | 303.00 ± 71.47 |
| GHTW | 6 | 2.7 | 371.00 ± 49.67 | 6 | 1.6 | 364.33 ± 65.56 |
| 3 risks factors | ||||||
| GBW | 37 | 16.8 | 384.00 ± 68.86 | 111 | 28.8 | 313.83 ± 67.57 |
| TBW | 13 | 5.9 | 411.31 ± 74.65 | 17 | 4.4 | 331.71 ± 63.30 |
| HBW | 6 | 2.7 | 408.83 ± 62.59 | 11 | 2.8 | 345.09 ± 76.04 |
| GTB | 11 | 5.0 | 368.91 ± 70.86 | 4 | 1.0 | 341.75 ± 64.86 |
| GHW | 2 | 0.9 | 366.50 ± 20.51 | 6 | 1.6 | 321.00 ± 67.36 |
| GHB | 4 | 1.8 | 318.50 ± 66.78 | 1 | 0.3 | 255.00 |
| HTW | 2 | 0.9 | 400.00 ± 46.67 | 3 | 0.8 | 304.67 ± 15.18 |
| GTW | - | - | - | 3 | 0.8 | 221.67 ± 76.14 |
| HTB | 2 | 0.9 | 408.00 ± 77.78 | - | - | - |
| GHT | - | - | - | 1 | 0.3 | 348.00 |
SUA—serum uric acid; G—elevated plasma glucose; H—low high density lipoprotein cholesterol; T—high triglycerides; B—elevated blood pressure; W—increased waist circumference.
Figure 4Clusters of MetS components and their association with SUA. SUA—serum uric acid; MetS—metabolic syndrome; G—elevated plasma glucose; H—low high density lipoprotein cholesterol; T—high triglycerides; B—elevated blood pressure; W—increased waist circumference.
The odds ratio and p-Value of specific clusters of MetS components.
| MetS Components Combination * | Crude | ||
|---|---|---|---|
| OR | 95% C.I. | ||
| 5 risks | |||
| GHTBW | 1.982 | 1.351–2.906 | <0.001 |
| 4 risks | |||
| GHTB | 0.475 | 0.156–1.450 | 0.191 |
| GHTW | 0.601 | 0.161–2.243 | 0.449 |
| GTBW | 0.927 | 0.585–1.469 | 0.748 |
| GHBW | 1.058 | 0.632–1.769 | 0.831 |
| HTBW | 1.030 | 0.511–2.076 | 0.935 |
| 3 risks | |||
| GBW | 0.653 | 0.436–0.978 | 0.039 |
| GTB | 0.655 | 0.206–2.082 | 0.473 |
| HBW | 1.282 | 0.481–3.418 | 0.619 |
| TBW | 1.056 | 0.493–2.262 | 0.889 |
* G—elevated plasma glucose; H—low high density lipoprotein cholesterol; T—high triglycerides; B—elevated blood pressure; W—increased waist circumference. All models adjusted for age and sex.